Mary Ann Yancey
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, PARP inhibition in cancer therapy, Cancer Treatment and Pharmacology, Hematological disorders and diagnostics, Cell death mechanisms and regulation
Most-Cited Works
- → A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors(2012)165 cited
- → Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies(2009)122 cited
- → Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study(2013)99 cited
- → Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease(2014)16 cited
- Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP(2009)
- → Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.(2012)5 cited
- → A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma(2011)3 cited
- → Sezary Syndrome: A Case Study of Cutaneous T-Cell Lymphoma(2009)3 cited
- → Role of immune-related conditions in smoldering myeloma and MGUS.(2012)3 cited
- → CD81: A Novel, Specific and Highly Sensitive Marker in Flow Cytometric Diagnosis of Plasma Cell Dyscrasia(2011)2 cited